Barclays Initiates Coverage on Juno Therapeutics Inc to Equal-weight

Barclays Initiates Coverage on Juno Therapeutics Inc(NASDAQ:JUNO). The shares have been rated Equal-weight. The rating by Barclays was issued on Jul 6, 2016.

In a different note, Raymond James said it Initiates Coverage on Juno Therapeutics Inc, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Outperform’ by the firm. Cowen & Company said it Initiates Coverage on Juno Therapeutics Inc, according to a research note issued on May 5, 2016. The shares have been rated ‘Outperform’ by the firm.

Juno Therapeutics Inc (JUNO) shares turned negative on Mondays trading session with the shares closing down -0.48 points or -1.73% at a volume of 62,05,712. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $28.85. The peak price level was also seen at $28.85 while the days lowest was $27.28. Finally the shares closed at $27.33. The 52-week high of the shares is $57.82 while the 52-week low is $22.37. According to the latest information available, the market cap of the company is $2,884 M.

Juno Therapeutics Inc(JUNO) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $9.78M. Analysts had an estimated revenue of $4.83M. Earnings per share were $-0.78. Analysts had estimated an EPS of $-0.55.

Several Insider Transactions has been reported to the SEC. On Jun 24, 2016, Richard Klausner (director) sold 12,000 shares at $40.71 per share price.Also, On Jun 21, 2016, Hyam Levitsky (EVP, Research & CSO) sold 12,418 shares at $42.98 per share price.On Jun 13, 2016, Steve Harr (CFO & Head, Corp. Development) sold 30,000 shares at $43.29 per share price, according to the Form-4 filing with the securities and exchange commission.

Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Juno Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Juno Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.